230 related articles for article (PubMed ID: 25589004)
1. Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis.
Han M; Guo L; Zhang Y; Huang B; Chen A; Chen W; Liu X; Sun S; Wang K; Liu A; Li X
Mol Neurobiol; 2016 Jan; 53(1):720-727. PubMed ID: 25589004
[TBL] [Abstract][Full Text] [Related]
2. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.
Wu B; Sun C; Feng F; Ge M; Xia L
J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
4. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
5. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of CD133 and nestin in patients with glioma: a population-based study.
Dahlrot RH; Hansen S; Jensen SS; Schrøder HD; Hjelmborg J; Kristensen BW
Int J Clin Exp Pathol; 2014; 7(7):3739-51. PubMed ID: 25120750
[TBL] [Abstract][Full Text] [Related]
7. Stem cell marker CD133 affects clinical outcome in glioma patients.
Zeppernick F; Ahmadi R; Campos B; Dictus C; Helmke BM; Becker N; Lichter P; Unterberg A; Radlwimmer B; Herold-Mende CC
Clin Cancer Res; 2008 Jan; 14(1):123-9. PubMed ID: 18172261
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and prognostic significance of COX-2 in glioma patients: a meta-analysis.
Wang J; Xiang C; Cai Y; Mei Z; Lu Q; Liu B; Zou L
Arq Neuropsiquiatr; 2022 Dec; 80(12):1254-1261. PubMed ID: 36580964
[TBL] [Abstract][Full Text] [Related]
9. Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma.
Rebetz J; Tian D; Persson A; Widegren B; Salford LG; Englund E; Gisselsson D; Fan X
PLoS One; 2008 Apr; 3(4):e1936. PubMed ID: 18398462
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis.
Wang W; Chen Y; Deng J; Zhou J; Zhou Y; Wang S; Zhou J
Tumour Biol; 2014 Oct; 35(10):9769-75. PubMed ID: 24973892
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: A comprehensive meta-analysis with 4729 patients involved.
Lu L; Wu M; Sun L; Li W; Fu W; Zhang X; Liu T
Medicine (Baltimore); 2016 Oct; 95(42):e5163. PubMed ID: 27759647
[TBL] [Abstract][Full Text] [Related]
12. High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma.
Zhang W; Chen H; Lv S; Yang H
Mol Neurobiol; 2016 May; 53(4):2354-60. PubMed ID: 25983032
[TBL] [Abstract][Full Text] [Related]
13. CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: a systematic review and meta-analysis.
Yiming L; Yunshan G; Bo M; Yu Z; Tao W; Gengfang L; Dexian F; Shiqian C; Jianli J; Juan T; Zhinan C
Oncotarget; 2015 Dec; 6(39):42019-27. PubMed ID: 26503471
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis.
Li X; Zhao H; Gu J; Zheng L
Int J Clin Exp Pathol; 2015; 8(10):12084-92. PubMed ID: 26722393
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis.
Zhong C; Wu JD; Fang MM; Pu LY
Tumour Biol; 2015 Sep; 36(10):7623-30. PubMed ID: 25921286
[TBL] [Abstract][Full Text] [Related]
16. CD105 Over-expression Is Associated with Higher WHO Grades for Gliomas.
Kong X; Wang Y; Liu S; Xing B; Yang Y; Li Y; Ren Z; Su C; Ma W; Wang R
Mol Neurobiol; 2016 Jul; 53(5):3503-3512. PubMed ID: 26884265
[TBL] [Abstract][Full Text] [Related]
17. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors.
Beier D; Wischhusen J; Dietmaier W; Hau P; Proescholdt M; Brawanski A; Bogdahn U; Beier CP
Brain Pathol; 2008 Jul; 18(3):370-7. PubMed ID: 18371181
[TBL] [Abstract][Full Text] [Related]
18. What is the clinical value of cancer stem cell markers in gliomas?
Dahlrot RH; Hermansen SK; Hansen S; Kristensen BW
Int J Clin Exp Pathol; 2013; 6(3):334-48. PubMed ID: 23412423
[TBL] [Abstract][Full Text] [Related]
19. The impact of survivin on prognosis and clinicopathology of glioma patients: a systematic meta-analysis.
Lv S; Dai C; Liu Y; Shi R; Tang Z; Han M; Bian R; Sun B; Wang R
Mol Neurobiol; 2015; 51(3):1462-7. PubMed ID: 25063470
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Implications of Transforming Growth Factor Beta in Pathological Grade and Prognosis of Glioma Patients: A Meta-Analysis.
Yang X; Lv S; Zhou X; Liu Y; Li D; Shi R; Kang H; Zhang J; Xu Z
Mol Neurobiol; 2015 Aug; 52(1):270-6. PubMed ID: 25148935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
